NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Tryp Therapeutics Inc (OTCQB: TRYPF)

 
TRYPF Technical Analysis
4
As on 1st May 2024 TRYPF STOCK Price closed @ 0.06 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.06 & Strong Sell for SHORT-TERM with Stoploss of 0.08 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

TRYPFSTOCK Price

Open 0.04 Change Price %
High 0.06 1 Day 0.02 50.00
Low 0.03 1 Week 0.02 50.00
Close 0.06 1 Month 0.04 200.00
Volume 30550 1 Year -0.04 -40.00
52 Week High 0.12 | 52 Week Low 0.01
 
OTCQB USA Most Active Stocks
SURG 1.80 23.29%
FNMAS 10.12 2.33%
FMCKJ 9.73 0.83%
BMIX 0.01 %
FNMA 3.16 4.98%
FMCC 3.08 5.48%
BTCWF 0.10 150.00%
EFSH 0.36 -7.69%
ALPP 3.56 0.00%
ALPP 3.56 0.00%
 
OTCQB USA Top Gainers Stocks
EMMLF 0.89 8800.00%
EWLUD 0.45 275.00%
BTCWF 0.10 150.00%
EGMLF 0.07 133.33%
ABEPF 0.02 100.00%
RELT 0.08 100.00%
RFHRF 0.02 100.00%
CRTG 0.02 100.00%
ZTLLF 0.02 100.00%
ALDS 0.02 100.00%
 
OTCQB USA Top Losers Stocks
USDR 0.08 -55.56%
RXRLF 0.14 -53.33%
RXRLF 0.14 -53.33%
SVTNF 0.01 -50.00%
SVTNF 0.01 -50.00%
AMMPF 0.01 -50.00%
INVU 0.01 -50.00%
GOCOF 0.02 -50.00%
SBMIF 0.10 -50.00%
BGAVF 0.01 -50.00%
 
 
TRYPF
Daily Charts
TRYPF
Intraday Charts
Whats New @
Bazaartrend
TRYPF
Free Analysis
 
TRYPF Important Levels Intraday
RESISTANCE0.12
RESISTANCE0.10
RESISTANCE0.09
RESISTANCE0.08
SUPPORT0.04
SUPPORT0.03
SUPPORT0.02
SUPPORT0.00
 
TRYPF Forecast November 2024
4th UP Forecast0.21
3rd UP Forecast0.16
2nd UP Forecast0.13
1st UP Forecast0.1
1st DOWN Forecast0.02
2nd DOWN Forecast-0.01
3rd DOWN Forecast-0.04
4th DOWN Forecast-0.09
 
TRYPF Weekly Forecast
4th UP Forecast0.14
3rd UP Forecast0.11
2nd UP Forecast0.10
1st UP Forecast0.08
1st DOWN Forecast0.04
2nd DOWN Forecast0.02
3rd DOWN Forecast0.01
4th DOWN Forecast-0.02
 
TRYPF Forecast2024
4th UP Forecast0.29
3rd UP Forecast0.22
2nd UP Forecast0.17
1st UP Forecast0.13
1st DOWN Forecast-0.01
2nd DOWN Forecast-0.05
3rd DOWN Forecast-0.1
4th DOWN Forecast-0.17
 
 
TRYPF Other Details
Segment EQ
Market Capital 19436346.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
TRYPF Address
TRYPF
 
TRYPF Latest News
 
Your Comments and Response on Tryp Therapeutics Inc
 
TRYPF Business Profile
Tryp Therapeutics Inc., a clinical stage pharmaceutical company, focuses on developing compounds with known activity and/or safety profiles for the treatment of rare or orphan diseases and other diseases. The company's lead development program is psilocybin-for-neuropsychiatry (PFN), which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its PFN program candidates include TRP-8802 for fibromyalgia, hyperphagia in prader-willi syndrome, and other therapies; and TRP-1001, an oral formulation of razoxane evaluating for the treatment of soft tissue sarcoma. Tryp Therapeutics Inc. has an agreement with the University of Michigan to perform research related to its psilocybin-for-neuropsychiatric disorders program; and a service agreement with Fluence to provide design and training for the psychotherapeutic portion of Tryp's clinical trial activities. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. The company was founded in 2019 and is headquartered in Kelowna, Canada. Address: 1665 Ellis Street, Kelowna, BC, Canada, V1Y 2B3
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service